Hepatitis C Trial, Recruiting (NCT06180590)

Hepatitis C Trial, Recruiting NCT06180590 Sponsor: The Third Affiliated Hospital of Guangzhou Medical University Condition: Hepatitis C

Printed from Voxsanity (voxsanity.com.au) — NCT06180590 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis C

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People between 20 and 70 years of age
People who have previously received a standard direct-acting antiviral treatment for hepatitis C
People whose hepatitis C virus (HCV) is still detectable in the blood after previous treatment
People whose doctor has them taking either once-daily Vosevi tablets (a combination of three antiviral medicines) or a combination of two antiviral medicines plus ribavirin twice a day as a rescue treatment
People who are expected to follow their treatment schedule reliably

Who may not be able to join:

People who also have HIV, hepatitis B, hepatitis D, or certain other infectious diseases
People who have liver cancer, advanced liver disease, autoimmune hepatitis, or significant problems with the kidneys, heart, lungs, or nervous system
People who are currently taking steroid medicines (such as glucocorticoids), chemotherapy drugs, anti-inflammatory medicines (such as NSAIDs), or medicines that affect the immune system
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xingfei Pan, PhD, The Third Affiliated Hospital of Guangzhou Medical University

Phone: 13662517686

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06180590

Sponsor: The Third Affiliated Hospital of Guangzhou Medical University

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis C

Trial contact: 13662517686

More information: https://clinicaltrials.gov/study/NCT06180590

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People between 20 and 70 years of age
People who have previously received a standard direct-acting antiviral treatment for hepatitis C
People whose hepatitis C virus (HCV) is still detectable in the blood after previous treatment
People whose doctor has them taking either once-daily Vosevi tablets (a combination of three antiviral medicines) or a combination of two antiviral medicines plus ribavirin twice a day as a rescue treatment
People who are expected to follow their treatment schedule reliably

Who may not be able to join:

People who also have HIV, hepatitis B, hepatitis D, or certain other infectious diseases
People who have liver cancer, advanced liver disease, autoimmune hepatitis, or significant problems with the kidneys, heart, lungs, or nervous system
People who are currently taking steroid medicines (such as glucocorticoids), chemotherapy drugs, anti-inflammatory medicines (such as NSAIDs), or medicines that affect the immune system
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The Third Affiliated Hospital of Guangzhou Medical University

Registry

ClinicalTrials.gov

Start date

28 February 2023

Est. completion

28 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The proportion of sustained virologic response after antiviral therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov